TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported further steps in its previously-announced restructuring. The restructuring is intended to further reduce expenditures and enable greater concentration of company resources on a planned Phase 1 clinical trial for its lead therapeutic candidate, TTX-MC138. The restructuring follows a strategic review of the company’s operations to identify areas in which it could delay or reduce expenditures, including a previously announced reduction in headcount.
Related news for (RNAZ)
- TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
- 24/7 Market News Snapshot 08 October, 2025 – TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ)
- Morning Market Brief: Biotech Names Stir as VENU Rockets on FireSuite Sales
- Today’s Top Performers: MoBot’s Market Review 10/08/25 09:00 AM
- TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company